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ABSTRACT
Background Use of cardiovascular medication has increased over time, especially for primary and secondary prevention, with polypharmacy
common.
Methods Review of published systematic reviews of the factors and outcomes associated with adherence to cardiovascular medication using
MEDLINE, Embase, CINAHL and PsycINFO databases. Quality was assessed using the AMSTAR tool.
Results Of 789 systematic reviews identiﬁed, 45 met the inclusion criteria and passed the quality assessment; 34 focused on factors associated
with adherence, and 11 on outcomes. High heterogeneity, both between and within reviews, precluded meta-analysis and so a pooled estimate
of adherence levels could not be derived. Adherence was associated with disease factors, therapy factors, healthcare factors, patient factors and
social factors, though with some inconsistencies. In total, 91% of reviews addressing outcomes reported that low adherence was associated
with poorer clinical and economic endpoints.
Conclusions Factors from across ﬁve key domains relate to non-adherence to cardiovascular medications, and may contribute to poorer clinical
outcomes. Interventions to improve adherence should be developed to address modiﬁable factors and targeted at those at highest risk of non-
adherence. Adherence research is highly heterogeneous to-date and efforts to standardize this should be implemented to improve
comparability.
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Introduction
Cardiovascular disease (CVD) is the leading cause of death
globally.1 Due to an ageing population and proliferation of
clinical trials, use of cardiovascular medication and polyphar-
macy have increased over time, which may contribute to
non-adherence to drugs. The US National Health and
Nutrition Survey (NHANES) found that 77% of adults
diagnosed with hypertension had been prescribed an antihy-
pertensive drug in 2010, compared to 63% in 2001.2
Additionally, the incidence of polypharmacy has risen, with
the percentage of patients taking multiple antihypertensives
in the US NHANES cohort growing by 11%.2 Within the
UK, the percentage of adults aged 65–84 years who are pre-
scribed three or more medications for chronic conditions
has increased by 50.5%,3 while for those aged over 85 it has
increased by 21.6%.3 This, in turn, has led to increased costs
to health services: NHS England dispensed over 1000 mil-
lion prescriptions in 2015, at an increase of 16.8% in costs
from 2005, totalling £9267 million for net ingredient
expenditure.4
Trial evidence of efﬁcacy will only translate into real-world
effectiveness if levels of adherence achieved in research stud-
ies can be replicated in the general population. In addition to
disease management, cardiovascular medications are used in
both primary and secondary prevention. Adherence may be
particularly problematic when medication is used as a long-
term, preventive strategy rather than for symptom relief.4
Patients’ perception of the risk associated with their disease
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may also play a role; for example, adherence to HIV medica-
tion has been shown to be 5% higher than adherence to
CVD medication.5,6 The aim of this study was to review the
existing published evidence of the factors and outcomes
associated with adherence to CVD medications.
Methods
Searches were conducted using MEDLINE (1996–present),
Embase (1996–present), CINAHL and PsycINFO (full
search strategy, Appendix 1). Inclusion was restricted to sys-
tematic reviews written in English, and duplicate publica-
tions removed using EndNote X7. Titles, then abstracts,
then full text were reviewed manually and included if they
studied factors associated with adherence to CVD medica-
tion for management of symptoms, primary, or secondary
prevention, or the association between adherence and health
outcomes. Reviews that included other conditions, as well as
CVD, were included but those focused exclusively on non-
CVD medication were excluded. Publications were excluded
if they focused on interventions to improve adherence,
adherence to non-medical interventions such as behavioural
change, or guidelines on management of adherence. Data
extraction included information on study aims, setting,
methods, search strategies and ﬁndings (overall adherence
levels and differences between sub-groups where reported).
Review of papers and data extraction was performed by
K.L., with a 10% sample independently reviewed by C.M.,
Findings were compared and disagreements discussed to
reach consensus.
The quality of eligible studies was assessed using the
AMSTAR tool,7 with papers scored out of 11 and categor-
ized into high quality (score of 9–11), reasonable quality
(score 6–8) or poor quality (score 3–5). Papers that scored
≤2 were rejected.
Results
The literature search initially identiﬁed 789 papers. After
review (741 papers removed) and quality assessment (3
removed) there were 45 eligible systematic reviews, 34 of
which dealt with factors associated with non-adherence and
11 on outcomes (Fig. 1).
Most reviews scored as high quality (n = 16, 36%), or rea-
sonable quality (n = 20, 44%) using the AMSTAR tool, but
many noted that the primary studies included were of a vari-
able standard. Results from data extraction of eligible reviews
are summarized in Supplementary Tables. Most primary
studies were conducted in the USA, Europe, and other devel-
oped countries, with only two systematic reviews centred on
low or middle income countries (LMICS).8,9 Half of the sys-
tematic reviews reported an overall estimate of adherence,
though this often had a wide range within each review, the
most extreme example ranging from 20 to 88%.10 Most sys-
tematic reviews included studies employing a range of meth-
ods to study adherence, with self-reporting most common,
followed by pharmacy claims, prescription reﬁlls and pill
counts. Electronic monitoring methods were reported in few-
er reviews (n = 11), possibly due to increased costs asso-
ciated with. Measures of adherence also varied, with many
studies comparing ‘good’ versus ‘bad’ adherence across a
speciﬁed threshold (≥0%). The two most common adher-
ence measures are the Medical Possession Ratio (MPR), the
‘number of days covered with medication in the reﬁll gap,
divided by the number of days in the reﬁll gap’,11 and
Proportion of Days Covered (PDC), or the ‘number of days
with medication supplied divided by the length of follow-
up’.11 Others considered the relative change in adherence
rates between groups, or the hazard ratio for non-adherence
against a reference category, though most reviews failed to
specify which of these metrics was used in the primary
studies.
Overall, 34 systematic reviews studied factors associated
with adherence,5,6,8–39 broadly categorized into: disease fac-
tors, therapy factors, healthcare factors, patient factors and
social factors6,40 (Table 1). Due to heterogeneity in study
design, quality, and operational deﬁnitions of adherence, it
was not possible to perform meta-analysis to derive a pooled
risk estimate associated with any individual factor. Instead,
detailed summaries of key factors are provided in Table 2.
Disease factors
Whilst adherence to medication for secondary prevention
following acute coronary syndrome was suboptimal,11 it was
nonetheless greater than adherence for primary preven-
tion.17,20,22 The effect of comorbidity on adherence varied
according to the condition. Patients with diabetes had higher
adherence to CVD medications,10,17 while depression almost
universally had a negative impact on adherence.10,14,32 The
duration of treatment was also important, with adherence
tending to decline over time.20
Therapy factors
In spite of heterogeneity in speciﬁc study characteristics,27
drug class was consistently associated with differences in
adherence.10,12,13,27,28 Adherence was best with angiotensin-
II receptor blockers (ARB’s),10,12,13,27,28 and in pooled
results, those prescribed ARB’s were 30–33% more likely to
be adherent overall compared to those prescribed other drug
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classes.10,27 Diuretics were associated with the lowest adher-
ence rates10,27 and lower persistence rates of any drug class,
ranging from 16 to 38% across studies,28 compared to beta-
blockers, BB’s (26–50%), calcium-channel blockers, CCB’s
(26–52%), angiotensin converting enzyme inhibitors, ACEi’s
(28–64%), and ARB’s (26–68%).28 Differences in side-effects
may partly explain these variations. Patients on ACEi’s are
68% more likely to develop a cough than those on ARB’s.12
At standard dose, side-effects are more prevalent among
patients taking thiazides (occurred in 9.9%), BB’s (7.5%) and
CCB’s (8.3%), compared with ACEi’s (3.8%),28 while ARB’s
(0%) are not associated with any side-effects.28
Dosage and treatment regimen were also associated with
adherence. Combination drugs were associated with greater
Fig. 1 Summary ﬂowchart of paper selection.
Table 1 Factors found to impact adherence
Disease factors Therapy factors Healthcare factors Patient factors Social factors
Disease treated5 Side-effects8,12,13 Relationship/communication with
physician6,14,15
Gender9,16,17 Socioeconomic
status6,10,17,19–21
Primary versus secondary disease
prevention11,17,20,22
Dosing regimen/
frequency5,8,22–24
Self-monitoring25 Age5,17 Level of education/
health literacy9,26
Comorbidity10 Drug class10,12,13,27,28 Cost/co-payments6,8,20,22,29–31 Making time for
appointments6,29
Ethnicity16
Depression10,14,32 Combination pill33–37 Routine place of care6,30 Stress/anxiety14 Minority status10
Diabetes10,17 Routine physician6,15,30 Forgetfulness6,14 Social support18
Duration of treatment20 Practitioner disagreement with
guidelines14
Lack of understanding8,14,15,29
Coronary artery calcium (CAC)
screening39
Alcohol consumption39
Patient beliefs/perception
of drugs6,8,14,15,21
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Table 2 Consistency of ﬁndings across reviews for key adherence factors
Factors Reviews Findings* Consistency
Disease
Primary versus secondary Mann et al. 2010; Lemstra et al. 2012;
Xu et al. 2016; Chen et al. 2015
Secondary +
Primary −
Similar ﬁndings across 100% of reviews.
• Of 10 studies comparing adherence or persistence
following MI to primary, 90% found better adherence in
MI group, with one study non-signiﬁcant.17
• Primary group 52% less likely to adhere than secondary
across 18 studies.20
• Overall adherence 46% better for secondary prevention
compared with primary prevention population at 1 year
(PDC).22
• Increased adherence following hospitalization in all
studies11 and trend continues with number of subsequent
hospitalizations.11
Comorbidity- diabetes Mann et al. 2010;
Lemstra and Alsabbagh 2014
Diabetes + Similar ﬁndings across both reviews, though variation at
study level.
• 54% Agreement across studies,17 with the remaining
studies non-signiﬁcant, and one found diabetes
comorbidity negatively impacted adherence.
• Review found 85% agreement across studies.10
Comorbidity- depression Khatib et al. 2014;
Lemstra and Alsabbagh 2014;
Eze-Nliam et al. 2010
Depression − • Depression common barrier, identiﬁed in 42% of self-
reported studies.14
• Meta-analysis of ﬁve studies (eight cohorts) found 11%
increased risk of nonadherence if depressed or prescribed
anti-depressants.10 Only one cohort found
inconsistencies.10
• Of two studies looking at depression, one found reduced
adherence and the other found a non-signiﬁcant odd
ratio.32
Therapy
Drug Class Matchar et al. 2008; Powers et al. 2012;
Lemstra and Alsabbagh 2014;
Kronish et al. 2011;
Bramlage et al. 2009
ARB’s +
ACEi’s +/−
CCB’s +/−
BB’s +/−
Diuretics –
• Found overall adherence was >90% for both ACEi and
ARBs. In 11 studies of persistence all found higher
continuation rate in ARBs (absolute difference of 7%
between groups).12 Whether or not this difference is
signiﬁcant is not stated.
• 39 Studies of adherence or persistence. Nine studies which
utilized pill counts found over 90% adherence to ARBs or
ACEi’s (no signiﬁcant difference) and persistence best with
ARBs compared to ACEi’s.13
• High level of agreement between studies: diuretics had an
increased risk of non-adherence compared with ACEi’s (RR
1.36), ARB’s (RR1.47), CCB’s (RR1.35).10 Pooled analysis
found higher risk of non-adherence in ACEi’s (RR1.30) and
CCB’s (RR1.33) compared to ARBs.10
• Across 17 studies, ARB’s consistently associated with
better adherence (non-signiﬁcant result in one study).27
Similarly diuretics found to be associated with poorer
adherence in all but two studies—one non-signiﬁcant
result and another favoured diuretics compared to BB’s.27
Continued
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Table 2 Continued
Factors Reviews Findings* Consistency
• ARB’s highest persistence in 87% of studies. Next best
persistence found in ACEi’s, CCB’s, and then BBs. Diuretics
lowest adherence rate in 100% of studies.28
Dosing frequency/
Treatment Regimen
Assawasuwannakit et al. 2015;
Bowry et al. 2011;
Iskedjian et al. 2002; Ingersoll et al. 2008
High dosing
freq. –
High
complexity +/−
Largely consistent, as number of dosages per day increases
adherence decreases.
• As age increased, the reduction in adherence associated
with dosing frequency became less signiﬁcant.5
• Divided into two subgroups: over 50% of patients take
two or more drugs per day and group where less than
50% fall into this category. Found no signiﬁcant difference
in adherence levels between subgroups.8
• Largely consistent across eight studies. Pooled results
found average adherence of 91% for once-daily, which
was 8% higher than for multiple daily dosing.23 Once daily
was also higher compared to twice daily dosing (5% better
for once daily).23 The difference in adherence rate
between twice and multiple daily dosing groups was not
signiﬁcant.
• Across six studies assessing dosing regimen, adherence
was best with once daily dosing compared to ≥2 per day
in all but one study.24 Disease may play a role—the study
which was not consistent looked speciﬁcally at patients
with congestive heart failure while other studies looked at
hypertension or CVD more generally.
Healthcare
Cost Bowry et al. 2011; AlGhurair et al. 2012;
Lemstra et al. 2012; Xu et al. 2016;
Marshall et al. 2012;
Maimaris et al. 2013,
Mann et al. 2014
Higher costs − • 82% of studies found signiﬁcant association between high
medication cost and non-adherence.8
• Financial burden and medication reimbursement cited as
reasons for patient non-adherence in seven self-reported
studies.6
• Pooled result across six studies found that patients liable
for co-payments are 28% less likely to be adherent.20
• Cost/co-payment most commonly studied factor (29%
studies).22
• Nine studies (seven US, two Brazil) found cost cited as a
barrier to non-adherence.29
• 14 Studies investigated medication costs or co-payments;
seven cohort studies found lower adherence with higher
costs, with one exception which found increased
adherence at much higher co-payment levels. Remaining
cross-sectional and case-control studies also found higher
adherence associated with lower costs.30
• Variable results across six studies. Some found greater
levels of signiﬁcance than others, though this related to
how much patients had to pay (i.e. less signiﬁcant if cost
lower—backs up principle).One study inconsistent—found
that higher co-payment reduced level of adherence, while
all other found opposite.31
Continued
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Table 2 Continued
Factors Reviews Findings* Consistency
Patient
Gender Lewey et al. 2013; Mann et al. 2010;
Nielsen et al. 2017
Female gender
+/-
Inconsistent. Varied with setting.
• 10% less likely to be adherent in females compared to
males across 53 studies.16 20% (n = 11) of studies found
no difference between genders, all conducted in
Canada.16
• Female gender associated with lower adherence in 61%
studies.17
• In four studies carried out in LMIC’s women were less
likely to adhere than men (OR 0.72).9
Age Assawasuwannakit et al. 2015;
Mann et al. 2010
Increasing age
+/−
• Signiﬁcant association between age and adherence in a
77% of studies, though not linear – adherence improved
with ages up to 65 yrs, then declined in older adults.5
Studies which did not observe this tended to have an older
study cohort and hence only found the decline in
adherence associated with older age (over 65).5
• Review only found improvement—8% increase in
adherence per 10 years increase in age, though maximum
age included was 66.7 years.17
Perceptions Bowry et al. 2011; Khatib et al. 2014;
Rashtid et al. 2014; AlGhurair et al. 2012;
McKenzie et al. 2015.
Perceive ill
health +/−
Perception of
reduction in
symptoms −
Perceive drugs
as addictive or
harmful −
• Negative perception of medication common barrier
reported in 52% of studies, 73% of which found statistical
signiﬁcance.8
• 30% of self-reported studies looking at patient factors
found patient perception of medications as a barrier.14
• Pooled: in 10 self-reported studies, perceptions about
consequences were reported as a barrier in 19% of
surveys.15
• Across 17 qualitative studies, found that patients with
either no/reduced symptoms or those with very severe
symptoms less likely to adhere as they believe they are not
ill or that it is futile as their disease has already progressed
too far.6
• Suggests patient perception may be a strong barrier to
adherence though gives no quantitative summary.21
Social
SES AlGhurair et al. 2012; Mann et al. 2010;
Alsabbagh et al. 2014;
Lemstra et al. 2012;
McKenzie et al. 2015;
Lemstra and Alsabbagh 2014.
Higher SES +
Lower SES −
• In 22% of self-reported studies socioeconomic factors
were cited as reducing adherence.6
• Overall found that those with a higher income more likely
to adhere,17 though inconsistent at study level—55%
found this effect while 44% found no difference between
low and high income groups.17
• Of 32 studies 17 found higher income associated with
higher adherence, 14 were non-signiﬁcant, while 1 found
lower adherence.19
• In 11 studies, odds of adhering improve with higher
income.20
• Lower income (concession card holders in Australia
healthcare system) found to have higher adherence. May
Continued
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adherence compared to equivalent drugs given separately,
ranging from 12% in one meta-analysis,33 to 29% in
another.34 Overall, adherence declined as the number of
doses per day increased,5,22–24 however, this effect was
reduced with increased age.5 In LMIC’s, approximately half
of studies looking at dosing complexity found a signiﬁcant
relationship between >1 daily dosing and non-adherence.8
Of ﬁve reviews that examined treatment regimens, two did
not take account of concomitant drug use as a factor,8,22
and a further two acknowledged this but stated they were
unable to analyse it given the data available.5,23 Only
Ingersoll et al.24 discussed polypharmacy; 66% of studies of
CVD medication found a positive inﬂuence of polyphar-
macy on adherence, despite increasing complexity being
found to have a reductive effect on adherence elsewhere.
The third study produced inconsistent ﬁndings.
Healthcare factors
Medication or appointments costs to the patient was com-
monly identiﬁed as inﬂuencing non-adherence,6,8,20,22,29–31
largely in US settings. One review reported cost or co-
payment as the most commonly studied factor related to
adherence (29% of studies).22 Patients who had to make co-
payments for treatment were at a 28% greater risk of non-
adherence, as they were less likely to collect their statins at
the appropriate time,20 and similar associations were found
across cohort studies of adherence to antihypertensives.30
The impact of co-payment on adherence varied depending
on the actual cost to the patient.31
Continuity of care was found to positively inﬂuence
adherence.6,15,30 In one review,30 nine of eleven studies
reported that it had a positive inﬂuence on patient awareness
of their condition, treatment, or control of hypertension.30
Patient factors
Gender was studied in three reviews.9,16,17 The majority of stud-
ies identiﬁed an association between gender and nonadherence,
with a 7–10% increased risk of non-adherence among
women. However, no association with gender was reported
in any of the eleven studies conducted in Canada16 and, in
studies conducted in low- and middle-income countries,
adherence was better among women.9 Age was also asso-
ciated with adherence: pooled results by Assawasuwannakit
et al.5 demonstrated a 9% improvement in adherence over a
13-year increase in age, from 40 to 53 years, among patients
with hypertension, however, no data was included for
patients over the age of 67 (age range: 6.9–66.7 years).5
Mann et al.17 found a ‘u-shaped’ relationship between nonad-
herence and age, with middle aged patients having better
adherence than adults aged between 18 and 50 years, or
above 70 years old.
Other patient factors associated with poorer adherence
include stress, anxiety and difﬁculty making time for
appointments.6,14,29 Alcohol consumption has a negative
affect on adherence14,39 across various chronic diseases,
though ﬁndings are inconsistent39 with insufﬁcient research
speciﬁc to hypertension.39
In studies using patient self-reporting to measure adher-
ence, forgetfulness and lack of knowledge were frequently
cited risk factors6,14 and patient’s perception of medication
and understanding of their disease were also important. In
one review investigating qualitative patient self-reported
studies (n = 15), three studies (20%) cited that patients dis-
continue treatment due to an initial lack of symptoms or fol-
lowing a reduction of symptoms,14 as they do not
understand the chronicity of their disease. Perceptions about
the medication itself can also have an impact; in the same
review, two self-reported studies (13%) cited patient fears of
reliance on cardiovascular drugs14 as a barrier to adherence.
Social factors
The literature on socioeconomic status (SES) is inconsistent.
In six systematic reviews reporting SES, two found no sig-
niﬁcant link6,21 although they did comment that other fac-
tors may have impacted this.21 In four reviews, high income
status was associated with better adherence ranging from 11
Table 2 Continued
Factors Reviews Findings* Consistency
be confounded (co-payments from concession card may
improve adherence).21
• Pooled analysis across nine studies found overall lower
adherence with lower income status.10
*Improved adherence (+), decreased adherence (−) or inconsistent (+/−) relationship with adherence.
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to 26% across reviews10,17,19,20 though there was consider-
able variation at individual study level. In the review by
Alsabbagh et al.,19 77.5% of studies found a positive associ-
ation between high SES and adherence, though all but one
of the remaining studies found high SES had a negative
impact on adherence.
Loke et al.26 investigated the relationship between health
literacy and adherence to CVD or diabetes medications, but
only one of seven cardiovascular studies found a signiﬁcant
association.
Outcomes of non-adherence
Eleven papers41–51 reviewed studies of outcomes associated
with non-adherence (Table 3), although the quality of these
was lower than the reviews of risk factors; 64 and 85%,
respectively, scoring reasonable or high quality. All but one
study found a signiﬁcant association between good adher-
ence and improved clinical or economic outcomes; the
exception of the Jongstra et al.51 review found no signiﬁcant
association between persistence of antihypertensive medica-
tion and cognitive function. Heterogeneity precluded meta-
analysis.
Bramlage and Hasford28 compared cost-effectiveness
across drug classes, and found newer drugs, ARB’s and
ACEi’s, outperformed the others in spite of being more
expensive per tablet. This may be due to greater adherence
to these drug classes10,12,13,27,28 which reduces later costs of
CVD treatment and adverse events. Bitton et al.43 found
that, in secondary prevention of CAD, patients who took
≤80% of their prescribed medication cost up to US$868
more per patient due to increased hospitalizations compared
with the adherent group. Furthermore, Shrouﬁ and Powles49
found improving adherence may reduce healthcare costs
more than earlier prescribing of statins would do, highlight-
ing this as an important aspect of disease management.
Discussion
Main ﬁnding of this study
Previous reviews have identiﬁed ﬁve main categories of fac-
tors associated with adherence; disease, therapy, healthcare,
patient and social factors.6,40 As drugs taken for prevention
of CVD are often intended for life-long use, adherence is
especially important; recognizing and addressing factors that
can improve adherence is vital in achieving maximum clin-
ical and cost effectiveness. Side-effects and differences in
adherence across drug classes could have important implica-
tions in prescribing of CVD drugs, while identifying differ-
ent population sub-groups, such as those with co-morbid
conditions, different genders, SESs or age groups, could be
important in informing dosage regimes or targeting inter-
ventions to improve adherence.
There is lack of consensus around the association
between adherence and outcomes, though nonetheless there
is some evidence suggesting that better adherence leads to
improved clinical and economic consequences, and there are
gaps in the literature yet to be addressed.47,48 There was
much heterogeneity across all studies with regards to how
adherence rates were assessed.
From these ﬁndings, it is apparent that poor adherence to
CVD medications has important consequences, and is a vital
area of study in order to reduce CVD morbidity and mortal-
ity and maximize the cost-effectiveness of treatment.
What is already known on this topic
It is well understood that adherence to drugs in chronic con-
ditions is sub-optimal and there is a dearth of research into
what the causative factors for this could be. However many
studies are restricted in that they investigate single factors in
isolation, or are of a relatively small scale and so have limited
power. In terms of systematic reviews, there has been much
research but little opportunity for meta-analysis owing to the
huge heterogeneity existing within the literature.
What this study adds
Many previous systematic reviews tend to focus on a par-
ticular factor, rather than looking across studies to include
factors from each of the ﬁve groups; disease, therapy, health-
care, patient and social factors.40 This review collates all of
this information into one place, to give an overview of fac-
tors identiﬁed throughout the literature. Few systematic
reviews dealt with outcomes of nonadherence, which gives
scope to develop research in this area.
Some factors were found to have similar associations with
adherence across the literature, a good example being the
class of drug prescribed. Newer CVD drugs, ARB’s and
Table 3 Outcomes associated with adherence
Outcome References
Blood pressure control 41,46,47,50
Myocardial infarction 46,48
CVD risk 42,45
CVD deaths 44,46,49
All-cause mortality 42,46
Hospital admissions 41,46
Healthcare costs 34
Cognitive function 51
8 JOURNAL OF PUBLIC HEALTH
Downloaded from https://academic.oup.com/jpubhealth/advance-article-abstract/doi/10.1093/pubmed/fdy088/5020710
by University of Glasgow user
on 04 June 2018
ACEi’s, were consistently found to have higher adherence
rates than BB’s CCB’s, and diuretics.10,12,13,27,28
On the other hand, some factors had inconsistent relation-
ships with adherence across primary studies and systematic
reviews: for instance, female gender was associated with an
overall higher risk of nonadherence in two reviews,16,17
though not elsewhere.9 It would be worthwhile identifying cul-
tural, societal or policy differences that may inﬂuence this.
Gender is a complex factor as it can be predictive of many
other confounding factors, for example, woman more com-
monly assume a care-giving role than men,16 and this has
been associated with poorer adherence.16 Hence, better sup-
port for caregivers and social care infrastructures could poten-
tially help contribute to better adherence in this subgroup.
Many factors are likely to impact each other. Age will be
inﬂuenced by different perceptions about health, increased
comorbidities, and lifestyle changes. Generally, age was asso-
ciated with an increase in adherence, though in the very old
there is decline.17 This could be related to disease factors,
for example, comorbidities common to old age, such as a
declining cognitive function and therefore an increased likeli-
hood to forget.5
Many perception barriers, such as belief that a reduction
of symptoms indicates that drugs are no longer required,14
or concerns of dependence to CVD medications,14 illustrate
a lack of understanding in some patients, and improved
communication is required.
Limitations of this study
Few systematic reviews were undertaken before the 1990s52
so it is unlikely that many papers would be missed by limit-
ing searches to the 1996 version of the databases.
This review is limited in that it was restricted to papers
written in the English language, contributing to potential
publication bias. The huge levels of heterogeneity within sys-
tematic reviews included, and between them, made meta-
analysis impossible and is a symptom of an area of research
that has been largely unstandardized in its implementation.
As this is an overview of systematic reviews, it would be
impossible to perform meta-analysis without unpicking the
individual studies to ensure none are over-represented.
Another issue is that the study design and method for calcu-
lating adherence have both been found to alter the rates of
adherence identiﬁed, though there is no gold standard within
the literature for analysing this. Many systematic reviews
failed to summarize operational deﬁnitions of adherence
used by primary studies, i.e. whether studies looked at adher-
ence as a continuous variable, or used a cut-off value above
which individuals were considered adherent.
Performing a systematic review of reviews is a good way
to collate and quality assess numerous studies published in
this ﬁeld; however, it is possible that important primary
papers have been missed by focusing only on reviews.
Conclusions
There is a range of modiﬁable and non-modiﬁable risk fac-
tors that have been associated with non-adherence to cardio-
vascular drugs, and these must be considered when
developing interventions to improve disease management.
Studies to-date are of variable quality and considerable het-
erogeneity. While some systematic reviews consider multiple
factors, many primary studies look at risk factors in isola-
tion, not accounting for the interplay between them, and
because of heterogeneity there was no opportunity to study
this quantitatively. This gives scope to conduct a primary
study looking at multiple adherence factors from across
these groups. Vitally important to this ﬁeld of research is an
agreed terminology and methodology, to allow comparisons
across different study populations to be made. Vrijens
et al.53 have deﬁned a taxonomy recommended for use, and
if used consistently by researchers it will greatly enhance the
value of adherence research.
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